JP2017513938A5 - - Google Patents

Download PDF

Info

Publication number
JP2017513938A5
JP2017513938A5 JP2017504294A JP2017504294A JP2017513938A5 JP 2017513938 A5 JP2017513938 A5 JP 2017513938A5 JP 2017504294 A JP2017504294 A JP 2017504294A JP 2017504294 A JP2017504294 A JP 2017504294A JP 2017513938 A5 JP2017513938 A5 JP 2017513938A5
Authority
JP
Japan
Prior art keywords
liposome
mupirocin
molar ratio
range
lipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017504294A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017513938A (ja
JP6676035B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IL2015/050376 external-priority patent/WO2015155773A1/en
Publication of JP2017513938A publication Critical patent/JP2017513938A/ja
Publication of JP2017513938A5 publication Critical patent/JP2017513938A5/ja
Application granted granted Critical
Publication of JP6676035B2 publication Critical patent/JP6676035B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017504294A 2014-04-10 2015-04-08 リポソームムピロシン Active JP6676035B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461977731P 2014-04-10 2014-04-10
US61/977,731 2014-04-10
PCT/IL2015/050376 WO2015155773A1 (en) 2014-04-10 2015-04-08 Liposomal mupirocin

Publications (3)

Publication Number Publication Date
JP2017513938A JP2017513938A (ja) 2017-06-01
JP2017513938A5 true JP2017513938A5 (cg-RX-API-DMAC7.html) 2018-04-26
JP6676035B2 JP6676035B2 (ja) 2020-04-08

Family

ID=53177332

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017504294A Active JP6676035B2 (ja) 2014-04-10 2015-04-08 リポソームムピロシン

Country Status (6)

Country Link
US (1) US10004688B2 (cg-RX-API-DMAC7.html)
EP (1) EP3142642B1 (cg-RX-API-DMAC7.html)
JP (1) JP6676035B2 (cg-RX-API-DMAC7.html)
CN (1) CN106659795B (cg-RX-API-DMAC7.html)
DK (1) DK3142642T3 (cg-RX-API-DMAC7.html)
WO (1) WO2015155773A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI754659B (zh) * 2016-08-08 2022-02-11 台灣微脂體股份有限公司 用於製備含有弱酸性劑之微脂體組合物的傳輸載體、方法及套組
EP3520819A1 (en) 2018-01-31 2019-08-07 Universität Basel Shear stress sensitive liposomes
US20220347096A1 (en) * 2019-10-03 2022-11-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Liposomal cannabinoids and uses thereof
EP4125809A1 (en) * 2020-03-25 2023-02-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Liposomal formulations comprising at1 receptor blockers and uses thereof
CN116270433B (zh) * 2023-03-14 2023-09-01 郑州大学第一附属医院 一种莫匹罗星软膏、制备方法及用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995015746A1 (en) * 1993-12-10 1995-06-15 The School Of Pharmacy Liposome delivery systems
DE69632859T2 (de) * 1995-04-18 2005-07-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Verfahren zur Arzneistoffbehandlung von Liposomen Zusammensetzung
US20060110441A1 (en) * 2004-10-28 2006-05-25 Harry Wong Lyophilized liposome formulations and method
WO2007005754A2 (en) 2005-07-01 2007-01-11 Alza Corporation Liposomal delivery vehicle for hydrophobic drugs
WO2007044745A1 (en) * 2005-10-11 2007-04-19 Biosynexus Incorporated Lantibiotic and mupirocin compositions for treating bacterial infections
US20090196918A1 (en) * 2008-02-01 2009-08-06 University Of Kentucky Research Foundation Liposomal formulations of hydrophobic lactone drugs in the presence of metal ions
CN102048693B (zh) * 2009-10-26 2013-08-21 石药集团中奇制药技术(石家庄)有限公司 具有苯磺酸衍生物内水相的脂质体
US20130337051A1 (en) * 2011-03-01 2013-12-19 To-Bbb Holding B.V. Advanced active liposomal loading of poorly water-soluble substances

Similar Documents

Publication Publication Date Title
Alavi et al. Utilization of chitosan-caged liposomes to push the boundaries of therapeutic delivery
JP2017513938A5 (cg-RX-API-DMAC7.html)
Gharib et al. Liposomes incorporating cyclodextrin–drug inclusion complexes: Current state of knowledge
US9968583B2 (en) Method of manufacture of liposome composition
EP4420679A3 (en) Lipids and lipid nanoparticle formulations for delivery of nucleic acids
MX2024001218A (es) Preparacion y almacenamiento de formulaciones liposomales de arn adecuadas para terapia.
JP2019501198A5 (cg-RX-API-DMAC7.html)
JP2008512446A5 (cg-RX-API-DMAC7.html)
EA201890367A1 (ru) Композиции и способы для лиофильных форм наночастиц
Zhai et al. Dermal nanocrystals from medium soluble actives–physical stability and stability affecting parameters
Alihosseini et al. Freeze-drying of ampicillin solid lipid nanoparticles using mannitol as cryoprotectant
JP2016529284A5 (cg-RX-API-DMAC7.html)
WO2009108828A3 (en) Solubility-enhanced forms of aprepitant and pharmaceutical compositions thereof
JP2018521083A5 (cg-RX-API-DMAC7.html)
US20190328665A1 (en) Liposome compositions encapsulating modified cyclodextrin complexes and uses thereof
JP6893245B2 (ja) 脂質ナノ粒子用膜材料組成物
JP6705933B2 (ja) リポソーム組成物およびその製造方法
WO2016040887A3 (en) Multilamellar lipid vesicle compositions and methods of use
TW200726485A (en) Liposomal delivery vehicle for hydrophobic drugs
RU2020137384A (ru) Средство для лечения опухоли и набор, содержащий липосомальную композицию гемцитабина
WO2015166987A1 (ja) リポソーム組成物及びその製造方法
JP6263609B2 (ja) リポソーム組成物及びその製造方法
Swarnakar et al. Effect of co-administration of CoQ10-loaded nanoparticles on the efficacy and cardiotoxicity of doxorubicin-loaded nanoparticles
BR112018068000A2 (pt) composições de nanolipossomas de geração de docetaxel direcionados ao receptor a2 de efrina (epha2)
EP3821911A4 (en) NUCLEIC ACID NANOPARTICLES, PHARMACEUTICAL COMPOSITION COMPRISING THEM, MEDICATION COMPRISING DOXORUBICIN, AND METHOD FOR PREPARING THEM